The mechanism of action of bortezomib involves blocking the 26S proteasome, a complex enzyme responsible for degrading ubiquitinated proteins. This inhibition leads to the accumulation of regulatory proteins that can induce apoptosis, or programmed cell death, in cancer cells. This unique approach helps in targeting cancer cells while sparing normal cells, making bortezomib an effective treatment option.
